论文部分内容阅读
2型糖尿病(T2DM)是严重威胁人类健康的慢性疾病之一,其患病率在全球呈现快速增长的态势。我国T2DM的诊治现状是,大约1/3的T2DM患者得到诊断,诊断患者中只有1/3进行治疗,治疗的患者中仅有1/3能够达标。因此,我国糖尿病的防治面临巨大的挑战。胰高血糖素样肽-1(glucagon-like peptide-1,GLP-1)研究是近年来糖尿病新药研发领域的热点方向之一,基于GLP-1药物包括GLP-1受体激动剂和二肽基肽酶-4(dipeptidyl
Type 2 diabetes mellitus (T2DM) is one of the most serious chronic diseases that threaten human health. Its prevalence is rapidly increasing worldwide. The current status of diagnosis and treatment of T2DM in China is that about one-third of patients with T2DM are diagnosed, and only one-third of the patients diagnosed are treated. Only one-third of patients treated can meet the standard. Therefore, the prevention and treatment of diabetes in our country faces a huge challenge. Glucagon-like peptide-1 (GLP-1) is one of the hottest research fields in recent years. Based on the fact that GLP-1 drugs include GLP-1 receptor agonist and dipeptide Peptidase-4 (dipeptidyl